10,902 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Brown Financial Advisors

Brown Financial Advisors acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,902 shares of the medical device company’s stock, valued at approximately $1,236,000.

A number of other institutional investors and hedge funds have also bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the 2nd quarter worth $25,000. Sachetta LLC lifted its stake in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of DexCom in the 1st quarter worth about $29,000. Riverview Trust Co bought a new position in shares of DexCom during the 1st quarter valued at about $32,000. Finally, DT Investment Partners LLC raised its holdings in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after buying an additional 315 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 1.6 %

NASDAQ:DXCM opened at $66.00 on Wednesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The company’s 50-day simple moving average is $71.85 and its 200 day simple moving average is $106.17. The firm has a market capitalization of $26.25 billion, a P/E ratio of 42.58, a PEG ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 earnings per share. As a group, analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,824 shares of company stock worth $126,390. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on DXCM shares. Piper Sandler reiterated an “overweight” rating and set a $90.00 price target on shares of DexCom in a research report on Monday, August 26th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Tuesday, September 24th. Robert W. Baird boosted their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Royal Bank of Canada reduced their price target on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Finally, Barclays reduced their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Six analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.